Rosetta Genomics Ltd. (ROSG)

0.43
0.07 20.56
OTC : Health Technology
Prev Close 0.36
Open 0.36
Day Low/High 0.36 / 0.45
52 Wk Low/High 0.23 / 2.75
Volume 425.14K
Avg Volume 86.30K
Exchange OTC
Shares Outstanding 5.93M
Market Cap 2.55M
EPS -9.40
P/E Ratio 0.05
Div & Yield N.A. (N.A)

Rosetta Genomics Establishes “Rosetta Green” As Majority-owned Subsidiary

Rosetta Genomics (NASDAQ: ROSG) announced today the legal formation of Rosetta Green as a majority-owned subsidiary with Rosetta Genomics holding a 76% ownership position in the new company.

Rosetta Genomics Reports First Quarter 2010 Financial Results

Rosetta Genomics, Ltd. (NASDAQ:ROSG), a leading developer of microRNA-based molecular diagnostics, today reported financial results for the three months ended March 31, 2010.

Rosetta Genomics And Collaborators To Present New Data At ASCO 2010 On Clinical Studies Involving MiRview Mets

In the Location line of the Poster Session information of the release dated May 26, 2010, the Abstract number should read: 4151 (sted 4153).

Joint Study By Rosetta Genomics And NYU Langone Medical Center Identifies Potential MicroRNA Drug Target For Mesothelioma

Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announced today that the results of a joint study with the NYU Langone Medical Center were published on...

Rosetta Genomics To Host First Quarter 2010 Conference Call On Thursday, May 27, 2010

Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, today announced that the Company will release financial results for the first quarter ended March ...

Rosetta Genomics Identifies 49 Novel MicroRNAs With Potential To Provide Novel Molecular Biomarkers And Drug Target Candidates

Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, announces the publication of a study entitled, “Discovery of microRNAs and other small RNAs in ...

Rosetta Genomics To Present At The 6th Annual Rodman And Renshaw Global Healthcare Conference

Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, announced today the Company will be presenting at the 6th Annual Rodman & Renshaw Global ...

Rosetta Genomics Announces New Patent Allowance And Provides Intellectual Property Update

Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, announced today the receipt of a new notice of allowance from the United States Patent and Trademark...

Rosetta Genomics Announces Publication Of Study On MicroRNA Expression For Lung Tumor Classification

Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, announces the publication of a study showing microRNA expression differentiates between primary lung...

Recent Study Demonstrating The Ability Of MiRview™ Squamous To Reliably Classify Non Small Cell Lung Cancer, To Be Presented At The 2nd European Lung Conference In Geneva, Switzerland

Rosetta Genomics, Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, announced today that Dr.

Rosetta Genomics To Present Multiple Posters At The American Association Of Cancer Research’s (AACR) 101st Annual Meeting

Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, announced today it will present multiple posters at the upcoming American Association of Cancer ...

Rosetta Genomics Now Processing Fine-Needle Aspirate Cell Block Samples For Lung Cancer Subclassification

Rosetta Genomics, Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announced today that starting April 1, 2010 physicians are able to send FNA cell block samples to Rosetta...

Rosetta Genomics Announces Publication Of The Development And Validation Process Of MiRview™ Mets In Modern Pathology

Rosetta Genomics, Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces publication of an article describing the development and validation process of miRview™ ...

Rosetta Genomics Receives Accreditation From The College Of American Pathologists (CAP)

Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, announced today it has been awarded accreditation by the Laboratory Accreditation Program of the...

Rosetta Genomics To Present At The 22nd Annual Roth OC Growth Stock Conference

Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer of microRNA-based molecular diagnostics, announced that Kenneth A.

Joint Study By Rosetta Genomics And NYU Langone Medical Center Identifies Single MicroRNA Biomarker For Prognosis Of Mesothelioma Patients

Joint Study By Rosetta Genomics And NYU Langone Medical Center Identifies Single MicroRNA Biomarker For Prognosis Of Mesothelioma Patients

Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announced today that the results of a joint study with the NYU Langone Medical Center were published...

Rosetta Genomics Announces Issuance Of Three U.S. Patents

Rosetta Genomics (NASDAQ:ROSG) today announced that the United States Patent and Trademark Office (USPTO) has issued three patents to the company covering the composition of matter of human microRNAs.

Rosetta Genomics Fortifies Patent Position With U.S. Allowance Of Claims Covering Human MicroRNAs MiR-21 And Hcmv-miR-UL112

Rosetta Genomics Fortifies Patent Position With U.S. Allowance Of Claims Covering Human MicroRNAs MiR-21 And Hcmv-miR-UL112

Rosetta Genomics (NASDAQ:ROSG) today announced that the United States Patent and Trademark Office has allowed claims in two patent applications.

LaBranche, Rosetta Genomics: Early Volume Plays

Several stocks trading near $5 were poised to move on above-average volume during Thursday's session.

Can Good Health Last for Medical IPOs?

The first part of the year was solid for new biotechs and health stocks.